Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage. AKI is characterized by abrupt deterioration in kidney function, manifested by an increase in serum creatinine level with or without reduced urine output.

 

DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more Acute Kidney Injury pipeline report offerings, click here: Acute Kidney Injury Pipeline Insight

 

Key Takeaways from the Acute Kidney Injury Pipeline Report

• DelveInsight’s Acute Kidney Injury Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Kidney Injury treatment. 
• The major Acute Kidney Injury companies include Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others are developing novel drug candidates to improve the Acute Kidney Injury treatment landscape.
• Key Acute Kidney Injury pipeline therapies in various stages of development include bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), UMC 119 06, Kidney specific amniotic mesenchymal stem cell therapy, RMC 035, SBI-101, QPI-1002, RMC035, MIB-626, RBT-9, Recombinant human alkaline phosphatase, XRx-101, SUL-138, UNI494, Timbetasin, and others.
• In March 2022, at the 27th International Conference on Advances in Critical Care Nephrology, AM-Pharma will deliver an overview of the current Phase III REVIVAL study.
• In September 2021, AM-Pharma agreed to an exclusive licensing deal with Kyowa Kirin giving Kyowa Kirin the rights to develop and sell ilofotase alfa in Japan.
• Angion and Vifor publicly published findings on ANG-3777 clinical trials in 2021, including a Phase II CSA-AKI trial and a Phase III DGF trial.

 

Request a sample and discover the recent breakthroughs happening Acute Kidney Injury pipeline landscape in @ Acute Kidney Injury Pipeline Outlook

 

A snapshot of the Acute Kidney Injury Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
ANG-3777	Angion Biomedica/Vifor Pharma	Phase II	Proto oncogene protein c met stimulant	Intravenous
Ilofotase alfa	AM Pharma	Phase III	Endotoxin inhibitors; Enzyme replacements	NA
ASP1128	Astellas Pharma	Phase II	Peroxisome proliferator-activated receptor delta modulators	Intravenous
Ruconest (Conestat alfa)	Pharming Technologies	Phase II	Complement C1 inhibitor protein replacements; Complement C1r inhibitors; Complement C1s inhibitors	Intravenous
RMC-035	Guard Therapeutics	Phase II	Alpha 1 microglobulin replacements	Intravenous
SBI-101	Sentien Biotechnologies	Phase I/II	Stem cell modulators	Parenteral
Timbetasin	RegeneRx Biopharmaceuticals	Preclinical	Actin modulators; Amyloid inhibitors	NA

 

Learn more about the novel and emerging Acute Kidney Injury pipeline therapies @ Acute Kidney Injury Clinical Trials

 

DelveInsight’s Acute Kidney Injury report covers around 40+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Request for free Sample Report to get detailed information about the recent developments in Acute Kidney Injury treatment landscape: Acute Kidney Injury Treatment and Medication

Scope of the Acute Kidney Injury Pipeline Report 

• Coverage: Global
• Key Acute Kidney Injury Companies: Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, and others.
• Key Acute Kidney Injury Pipeline Therapies: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others.
• Therapeutics Assessment By Mechanism of Action: Alpha 1 microglobulin replacements, Antioxidants, Free radical scavengers, Haemoglobin inhibitors, Decyclizing heme oxygenase inhibitors, Immunomodulators, Virus replication inhibitors, CD28 antigen modulators, Immunomodulators, Cell replacements, RNA interference, Tumour suppressor protein p53 inhibitors

 

To know more about the latest FDA approvals of Acute Kidney Injury drugs, click here: Acute Kidney Injury therapies and drugs

 

Table of Contents:

Introduction

Executive Summary

Acute Kidney Injury: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Acute Kidney Injury – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Acute Kidney Injury Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Teprasiran: Quark-Pharmaceuticals

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

EH 301: Elysium Health

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Centhaquine: Pharmazz

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

• Comparative Analysis

Timbetasin: RegeneRx Biopharmaceuticals

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Acute Kidney Injury Key Companies

Acute Kidney Injury Key Products

Acute Kidney Injury- Unmet Needs

Acute Kidney Injury- Market Drivers and Barriers

Acute Kidney Injury- Future Perspectives and Conclusion

Acute Kidney Injury Analyst Views

Acute Kidney Injury Key Companies

Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services